Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities

v3.2.0.727
Accrued Expenses and Other Long-Term Liabilities
6 Months Ended
Jun. 30, 2015
Payables and Accruals [Abstract]  
Accrued Expenses and Other Long-Term Liabilities
10. Accrued Expenses and Other Long-Term Liabilities
  
In December 2012, the Company acquired certain manufacturing rights from Ovamed GmbH (“Ovamed”) and agreed to pay an aggregate of $1.5 million, in three installments of $0.5 million on December 12, 2014, 2015 and 2016, respectively. As of June 30, 2015, the Company had not made any payments to Ovamed. On February 27, 2015, Ovamed, the Company’s supplier and manufacturer of TSO, filed for insolvency in Germany, a process similar to U.S. bankruptcy. The accrual is recorded on the Company’s Unaudited Condensed Consolidated Balance Sheets as a current accrued expense of $1.5 million as of June 30, 2015, as a result of the bankruptcy notification. This obligation was recorded at its full value; accretion of the obligation was nil and $38,000 for the three month period ended June 30, 2015 and 2014, respectively, and $167,000 and $75,000 for the six months ended June 30, 2015 and 2014, respectively, and is recorded as interest expense Unaudited Condensed Consolidated Statements of Operations. On April 20, 2015, the Company decided to no longer pursue the development of TSO. As a result, the Company terminated all on-going TSO trials including its Phase 2A clinical trial in pediatric patients with autism spectrum disorder. A preliminary analysis of data from this trial failed to demonstrate any signal of activity. 
 
Accrued expenses and other long-term liabilities consisted of the following:
 
 
 
June 30, 2015
 
December 31, 2014
 
Accrued expenses:
 
 
 
 
 
 
 
Professional fees
 
$
359
 
$
837
 
Salaries, bonuses and related benefits
 
 
640
 
 
598
 
Accrued milestone, CNDO SO
 
 
500
 
 
-
 
Accrued severance
 
 
6
 
 
38
 
Ovamed manufacturing rights - short term component
 
 
1,500
 
 
1,000
 
Research and development
 
 
623
 
 
832
 
Lease impairment
 
 
165
 
 
165
 
Other
 
 
593
 
 
213
 
Total accrued expenses
 
$
4,386
 
$
3,683
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
Ovamed manufacturing rights – long-term component
 
 
-
 
 
334
 
Long-term lease abandonment charge
 
 
144
 
 
268
 
Deferred rent
 
 
120
 
 
120
 
Total other long-term liabilities
 
$
264
 
$
722